You are here: Industry Insights > Takeda

News List

Takeda takes the lead on Finch's ulcerative colitis candidate FIN-524 pharmatimes
August 12, 2021
Takeda has elected to accelerate the transition of development responsibility for Finch Therapeutics' FIN-524, an investigational oral microbiome therapy in development for ulcerative colitis.
Takeda Breaks Ground on New Manufacturing Facility contractpharma
August 06, 2021
The $126 million investment increases the site’s capacity to manufacture additional products for the rare disease community.
Takeda and Frazier Healthcare Partners collaborate to develop clinical-stage norovirus vaccine candidate expresspharma
August 03, 2021
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners have collaborated to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialise Takeda’s norovirus vaccine candidate.
Takeda and Frazier to launch HilleVax for norovirus vaccine development pharmaceutical-technology
August 02, 2021
Takeda Pharmaceutical and Frazier Healthcare Partners have partnered to launch a biopharmaceutical company named HilleVax to develop and market Takeda’s norovirus vaccine candidate, HIL-214 (previously TAK-214).
Takeda expands Covid-19 vaccine supply deal with Moderna pharmaceutical-technology
July 22, 2021
Takeda Pharmaceutical has entered a new agreement with Moderna and the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to import and supply 50 million doses of Moderna’s mRNA Covid-19 vaccine in the country.
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders firstwordpharma
July 21, 2021
Takeda Pharmaceutical Company Limited today announced the results of a phase 3 trial investigating the efficacy and safety of recombinant von Willebrand factor (rVWF) prophylaxis,1 one of the 12 abstracts being presented at the International Society.
Takeda’s dengue vaccine bags positive long-term efficacy results pharmatimes
May 26, 2021
Japanese pharma company Takeda has announced that its dengue vaccine candidate TAK-003 demonstrated continued protection through three years after vaccination, regardless of previous exposure to the disease.
Takeda Pharmaceutical reports decline in FY2020 revenue pharmaceutical-technology
May 13, 2021
Takeda Pharmaceutical has reported a 2.8% year-on-year (YOY) decrease in its reported revenue to JPY3,197.8bn ($29.4bn) during the fiscal year 2020 (FY2020) ended 31 March 2021.
Takeda sells Japan’s non-core products portfolio to Teijin Pharma pharmaceutical-technology
April 02, 2021
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma for $1.25bn (JPY133bn).
EMA accepts regulatory submission for Takeda’s dengue vaccine candidate europeanpharmaceuticalreview
March 29, 2021
The submission is the first in a series that will include dengue-endemic countries, it includes long-term Phase III safety and efficacy data for the TAK-003 vaccine candidate.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page